Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Engage Grants Program

University of British Columbia

$25,000.00

Role of granzyme B in the aging retina

FY 2017-18

Summary
The goal of the project is to identify the distribution of an important family of enzymes, the Granzymes, in theaging eye. Granzymes are serine proteases that were shown by our partner, ViDA Therapeutics, to play animportant role in the abnormal degradation of extracellular proteins and tissue matrices in many parts of thebody. To date, there are no studies on the role of Granzymes in the eye, an organ that contains an importantextracellular structure called Bruch's Membrane (BM). As the eye ages, the extracellular matrix (ECM) withinBM undergoes dramatic remodelling, hypothesized to lead to a dysfunctional blood-eye barrier. Recent studieshave shown that loss of barrier function in the outer retina causes 1) retinal cell death, 2) pro-inflammatoryevents and 3) abnormal angiogenesis and vascular permeability.The research proposed will provide relevant and novel information about the cellular distribution ofGranzyme B in the aging eye that will allow us to understand Granzyme B's role in ECM remodeling. Thehypothesis is that with aging, levels of Granzyme B increase in the choroidal tissues, leading to a compromisedBM and concomitant loss of tight junctional proteins, dysregulated barrier function, increased vascularpermeability, angiogenesis and pro-inflammation. Eye tissues from postmortem human donors (ranging from16yr to 80yrs of age) and wild type mice (C57Bl/6J, 3 to 18 months of age) will be assessed for longitudinalchanges in protein levels of Granzyme B, cytokines (IL1b; IL1a), tight junctional proteins (ZO-1, cadherins),and angiogenic factors (VEGF, bFGF). Immunohistochemistry will identify the laminar distribution whileantibody-based multiplexes will provide quantitative values (pg/mL) of these molecules in the retina. Opticalimaging of the retina in Granzyme B knock-out mice and in aged mice treated with Granzyme B inhibitors willassess Granzyme B-induced changes in retinal structure in vivo. Key benefits include new target areas forpartner's proprietary Granzyme B inhibitors. Future economic and social benefits include potential newtreatments for Canadians suffering from chronic ocular inflammation.
Program
Engage Grants Program
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
522171-2017
Name nom
Matsubara, Joanne
Department département
Ophthalmology and Visual Sciences
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1554
Committee name en
Pacific Internal Decision Committee
Committee name fr
Comité de décision interne pour le Pacifique
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
6401
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Pathology
Research subject fr
Pathologie
Partie
1
Nb partie
1
Application title
Role of granzyme B in the aging retina
Keyword
NSERC
Application summary
The goal of the project is to identify the distribution of an important family of enzymes, the Granzymes, in theaging eye. Granzymes are serine proteases that were shown by our partner, ViDA Therapeutics, to play animportant role in the abnormal degradation of extracellular proteins and tissue matrices in many parts of thebody. To date, there are no studies on the role of Granzymes in the eye, an organ that contains an importantextracellular structure called Bruch's Membrane (BM). As the eye ages, the extracellular matrix (ECM) withinBM undergoes dramatic remodelling, hypothesized to lead to a dysfunctional blood-eye barrier. Recent studieshave shown that loss of barrier function in the outer retina causes 1) retinal cell death, 2) pro-inflammatoryevents and 3) abnormal angiogenesis and vascular permeability.The research proposed will provide relevant and novel information about the cellular distribution ofGranzyme B in the aging eye that will allow us to understand Granzyme B's role in ECM remodeling. Thehypothesis is that with aging, levels of Granzyme B increase in the choroidal tissues, leading to a compromisedBM and concomitant loss of tight junctional proteins, dysregulated barrier function, increased vascularpermeability, angiogenesis and pro-inflammation. Eye tissues from postmortem human donors (ranging from16yr to 80yrs of age) and wild type mice (C57Bl/6J, 3 to 18 months of age) will be assessed for longitudinalchanges in protein levels of Granzyme B, cytokines (IL1b; IL1a), tight junctional proteins (ZO-1, cadherins),and angiogenic factors (VEGF, bFGF). Immunohistochemistry will identify the laminar distribution whileantibody-based multiplexes will provide quantitative values (pg/mL) of these molecules in the retina. Opticalimaging of the retina in Granzyme B knock-out mice and in aged mice treated with Granzyme B inhibitors willassess Granzyme B-induced changes in retinal structure in vivo. Key benefits include new target areas forpartner's proprietary Granzyme B inhibitors. Future economic and social benefits include potential newtreatments for Canadians suffering from chronic ocular inflammation.